Sernova Corp has performed steadily this week, holding its ground amid limited news.
Sernova Corp (SVA.TO) reported no significant changes in its stock price this week, remaining stable at C$0.15. The company has a recent history of FDA designations and financial moves, allowing it to navigate the health care sector without major headlines affecting its stock performance.
Advertisement
Sernova Corp
SVA.TO
SVA.TO
Sernova Corp
WealthAwesomeMarket cap
$41.54M
52W high
$0.20
52W low
$0.10
1W change
+0.00%
Beta
0.64
Analyst Price Targets
Based on analyst covering SVA
Wall Street analysts forecast SVA stock price to rise 309.1% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$0.45
+309.1% Upside
Current Price
C$0.11
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on SVA's historical volatility
30-Day Vol
61.9%
Annualized
90-Day Vol
81.2%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$0.09
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$0.10 | C$0.08 โ C$0.13 |
| 60 trading days | C$0.10 | C$0.07 โ C$0.13 |
| 90 trading days | C$0.09 | C$0.06 โ C$0.13 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Sernova Corp's stock has been stable over the past week despite recent FDA designations and financial developments. Investors should consider the company's long-term potential in the health care sector while keeping an eye on future news.
Sernova Corp's stock remains at C$0.15 with a YTD decline of 12%.
Despite the year-to-date drop, the stock's current price is still within 50% of its 52-week range, showing some resilience against broader market challenges.
Bull case
The FDA's Orphan Drug Designation could boost Sernova's marketability and funding opportunities, which might lead to increased investor confidence.
Bear case
The absence of significant news and a high beta could signal volatility. Additionally, the company's negative profit margin and return on equity (ROE) may raise concerns for risk-averse investors.
Price Action Overview
Sernova Corp's stock closed at C$0.15, unchanged for the day. Over the past week, the stock has remained flat, suggesting a consolidation phase for investors. Year-to-date, the stock has decreased by 12%, and it has seen a slight decline of 4.35% over the past month.
Recent Company News
Advertisement
Currently, there are no major headlines impacting Sernova Corp this week. However, earlier reports indicated that the company received FDA Orphan Drug Designation for its autologous islet transplantation therapy, which could enhance its market position in the future. As the company continues to develop its product pipeline, investors may want to watch for any future announcements.
Technical Picture
From a technical perspective, Sernova Corp's stock is trading above its 50-day moving average of C$0.12, indicating a positive short-term trend. The stock is also at the high end of its 52-week range, which spans from C$0.10 to C$0.20. With a beta of 0.64, the stock shows lower volatility compared to the market. Notably, the trading volume has been significantly higher than its 20-day average, with the latest volume reported at 1,335,995 shares compared to an average of 77,722 shares.
Insider Activity
There is no recent insider activity reported for Sernova Corp, which may suggest stability in management and operations.
Conclusion
Sernova Corp's stock remains at C$0.15, with no change in price for the day. The company continues to operate in a challenging environment but holds potential with its recent FDA designation. Investors should stay informed on further developments, as they could impact future stock performance.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile โโ Reviewed by Certified Financial Professionals
This content has been reviewed by CFAยฎ charterholders and Certified Financial Planners (CFPยฎ) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFAยฎ charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFPยฎ professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
โ ๏ธ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
